- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00817817
A Study to Determine the Efficacy and Safety of Two Mometasone Dry Powder Inhalers in the Treatment of Asthma (Study P02524)
1 februari 2022 bijgewerkt door: Organon and Co
An Open-Label, Comparative, Randomized, Parallel, Multicenter Study to Determine the Efficacy and Safety of Two Dry Powder Inhalers (DPIs) Used for the Application of Mometasone in the Treatment of Asthma
This is an open-label, comparative, randomized, parallel, multicenter study in asthmatics to determine whether the administration of dry powder inhaled mometasone furoate (MF) 400 μg in a monodose capsule device would be comparable to administration of powder inhaled MF 400 μg in a multidose device.
Studie Overzicht
Studietype
Ingrijpend
Inschrijving (Werkelijk)
93
Fase
- Fase 3
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
18 jaar en ouder (Volwassen, Oudere volwassene)
Accepteert gezonde vrijwilligers
Nee
Geslachten die in aanmerking komen voor studie
Allemaal
Beschrijving
Inclusion Criteria:
- Must be >=18 years of age, of either gender & of any race.
- Must have had a diagnosis of asthma for at least 6 months, characterized by recurrent episode of wheezing, breathlessness, chest tightness & coughing.
- Baseline FEV1 must be >=55% and <=85% of predicted at the Screening Visit, when all restricted medications have been withheld for the specified intervals.
- Must demonstrate evidence of an increase in absolute FEV1 of >=12%, with an absolute volume increase of at least 200 mL, after reversibility testing at the Screening Visit or documented in the patients chart reversibility up to 1 year previous to inclusion.
- Must be free of any clinically significant disease (other than asthma), that would interfere with study evaluations.
- Must be willing to give written informed consent and be able to adhere to dose & visit schedules.
- Must agree to inform their own usual treating physician about their participation in the study.
- Non-pregnant women of childbearing potential must be using a medically acceptable, adequate form of birth control. This includes: 1) hormonal contraceptive as prescribed by a physician (eg, oral combined, hormonal implant, depot injectable); 2) medically prescribed IUD; 3) condom in combination with a spermicide; 4) Monogamous relationship with a male partner who has had a vasectomy or is using a condom plus spermicide during the study. They must have started this birth control method at least 3 months prior to Screening (with the exception of condom in combination with a spermicide), & must agree to continue its use for the duration of the study. Women of childbearing potential who are not currently sexually active must agree and consent to using a double-barrier method should they become sexually active during the course of this study. Women who are surgically sterilized or are at least 1 year postmenopausal are considered not to be of childbearing potential. However, all female subjects must have a urine pregnancy test obtained at screening, prior to initiation of treatment, & at the end of the trial, which must be negative.
Subjects who did not use the following medication prior to inclusion:
- Beta 2 agonist short-acting (inhaled, oral)(12 Hours)
- Beta 2 agonist long-acting (inhaled)(48 Hours)
- Ipratropium bromide (12 hours)
- Cromolyn sodium, nedocromil (7 days)
- Astemizole (3 months)
- Cetotifeno (3 months)
- Another investigational drug (1 month)
- Theophyline (2 weeks)
- Antihistamines (7 days)
- Anticholinergics (7 days)
- Leukotriene modifiers (2 weeks)
- Oral decongestant long-acting (72 hours)
- Oral decongestant short-acting (24 hours)
- Oral corticosteroids (1 month)
- Injected corticosteroids (3 months)
- Inhaled corticosteroids (24 hours)
- Baseline portable Peak Expiratory Flow at the Screening Visit must be >50% of predicted. The best value out of 3 must be considered.
Exclusion Criteria:
- Women who are pregnant, breast-feeding, or are pre-menarcheal.
- Have used any investigational drug within the last 30 days or who have ever been treated with any investigational antibody for asthma or rhinitis.
- Are receiving escalating doses of immunotherapy, oral immunotherapy or short course (rush) immunotherapy.
- No subject participating in this study may participate in this same study at another investigational site or in any other investigational study at the same time.
- Must not be randomized into the study more than once.
Subjects with the following clinical conditions/demography:
- Allergic to corticosteroids or beta-agonists.
- Required hospitalization for asthma control within the previous 3 months.
- Required ventilator support for respiratory failure secondary to their asthma within the last 5 years.
- Treated in the ER (for a severe asthma exacerbation), or admitted to the hospital for management of airway obstruction, on 2 or more occasions within the last 6 months.
- Clinical evidence of emphysema, chronic bronchitis, bronchiectasis, or cystic fibrosis.
- Significant history of renal, hepatic, cardiovascular, metabolic, neurologic, hematological, respiratory, gastrointestinal, cerebrovascular, or other significant medical illness or disorder which, in the judgment of the investigator, could have interfered with the study, or required treatment which might have interfered with the study.
- Requiring the use of >12 puffs per day of Salbutamol on any 2 consecutive days between study visits.
- Experienced upper or lower respiratory tract infection within the previous 2 weeks prior to enrollment.
- Clinically relevant abnormal baseline vital sign.
- Clinically significant abnormalities on chest x-ray at the Screening Visit or within the previous 6 months.
- Evidence of clinically significant oropharyngeal candidiasis.
- Smokers, or ex-smokers who are smoking or have smoked at least 20 years/pack or subjects who are smoking in the last 6 months.
- Known to be HIV positive.
- Known to be illicit drug abusers.
- HPA axis disturbances.
- Showing any clinical condition considered to be severe.
- Severe airflow obstruction showing to be life-threatening.
- Baseline FEV1 <55% of the predicted normal.
- Uncontrolled hypertension.
- Suspected pneumonia, pneumothorax, pneumomediastinum, pulmonary TB, alpha-1 anti-trypsin deficiency, lung mycosis or pulmonary cystic fibrosis.
- History of thoracic surgery or any previous malignancy of the lung,
- Significant heart disease,
- Receiving beta-adrenergic blocking agents.
- Presenting baseline portable peak expiratory flow at the Screening Visit <=50% of predicted. The best value out of 3 must be considered.
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Groep 2
|
One evening dose of dry powder inhaled MF 400 μg (Multidose device).
Andere namen:
One evening dose of dry powder inhaled 400 μg (400 μg capsules - Monodose).
Andere namen:
|
Experimenteel: Groep 1
|
One evening dose of dry powder inhaled MF 400 μg (Multidose device).
Andere namen:
One evening dose of dry powder inhaled 400 μg (400 μg capsules - Monodose).
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
The assessment of efficacy will be done by spirometry, determining the difference in FEV1 and PEFR measured by spirometry on baseline, 7, 14, 28, 42 and 56 days after initiation of MF dry powder inhaler (DPI) therapy.
Tijdsspanne: Baseline, 7, 14, 28, 42, and 56 days after initiation of MF DPI therapy.
|
Baseline, 7, 14, 28, 42, and 56 days after initiation of MF DPI therapy.
|
To determine the number of puffs/day of rescue medication (Salbutamol).
Tijdsspanne: Daily
|
Daily
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
To compare the PEFR daily measurements obtained by Peak flow Meter used by subjects at home.
Tijdsspanne: Daily
|
Daily
|
To compare the daily scores for asthma symptoms and sleep quality.
Tijdsspanne: Every morning
|
Every morning
|
To compare the evaluation of response to therapy made by the investigator at each visit compared to the Baseline visit.
Tijdsspanne: Visits 2 to 6.
|
Visits 2 to 6.
|
To determine and compare the safety (HPA axis evaluation) of both treatments using 400 μg MF DPI once daily in adult subjects with asthma.
Tijdsspanne: Visits 2 to 6
|
Visits 2 to 6
|
To determine and compare the safety (clinical laboratory measurements) of both treatments using 400 μg MF DPI once daily in adult subjects with asthma.
Tijdsspanne: Visit 6
|
Visit 6
|
To determine and compare the tolerability (adverse events) of both treatments using 400 μg MF DPI once daily in adult subjects with asthma.
Tijdsspanne: Visits 2 to 6.
|
Visits 2 to 6.
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Sponsor
Publicaties en nuttige links
De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Werkelijk)
1 oktober 2002
Primaire voltooiing (Werkelijk)
1 mei 2003
Studie voltooiing (Werkelijk)
1 mei 2003
Studieregistratiedata
Eerst ingediend
6 januari 2009
Eerst ingediend dat voldeed aan de QC-criteria
6 januari 2009
Eerst geplaatst (Schatting)
7 januari 2009
Updates van studierecords
Laatste update geplaatst (Werkelijk)
2 februari 2022
Laatste update ingediend die voldeed aan QC-criteria
1 februari 2022
Laatst geverifieerd
1 februari 2022
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- P02524
Plan Individuele Deelnemersgegevens (IPD)
Bestudeer gegevens/documenten
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op MF
-
Bausch & Lomb IncorporatedVoltooid
-
Purdue UniversityUniversity of OregonNog niet aan het werven
-
Purdue UniversityNog niet aan het werven
-
VA Office of Research and DevelopmentNog niet aan het wervenDepressie | Ongerustheid | Posttraumatische stressstoornis (PTSS)Verenigde Staten
-
Coopervision, Inc.Voltooid
-
Campus Bio-Medico UniversityUniversity of Rome Tor Vergata; University Hospital of Ferrara; Arcispedale Santa... en andere medewerkersBeëindigdIschemische beroerte | Beroerte, acuutItalië
-
Innovative MedicalVoltooidStaarVerenigde Staten
-
National Taiwan University HospitalOnbekendSecundair maligne neoplasma van de wervelkolomTaiwan
-
Vastra Gotaland RegionWerving
-
Universitaire Ziekenhuizen KU LeuvenVoltooid